Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04739969 · ClinicalTrials.gov registry record · NA
Rapid Acting Transcranial Magnetic Stimulation
A NA study of Treatment-Resistant Depression, sponsored by Stanford University.
- Active
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT04739969: Active NA study of Treatment-Resistant Depression, sponsored by Stanford University.
NCT04739969 is a NA study of Treatment-Resistant Depression that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 100 participants, below the 372-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04739969, a NA study of Treatment-Resistant Depression, is active but no longer recruiting, sponsored by Stanford University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression. In a double-blind, randomized, sham-controlled fashion, half the participants will receive accelerated theta-burst stimulation while half will receive sham treatment.
Primary Outcome
The Montgomery-Åsberg Depression Rating Scale (MADRS), is a ten item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. Remission is defined as MADRS ≤10.
Conditions Studied
Interventions
- DEVICE Active TBS-DLPFC
- DEVICE Sham TBS-DLPFC
Study Locations (1)
California
- Department of Psychiatry and Behavioral Sciences, Stanford School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-06-15 |
| Est. Completion | 2025-12 |
| Phase | NA |
What the registry record for NCT04739969 still lists
NCT04739969 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 372-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Treatment-Resistant Depression appearing as the primary indexed condition, and to 2 interventions - of which Active TBS-DLPFC is the first listed.
NCT04739969 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04739969 about?
NCT04739969 is a clinical study titled "Rapid Acting Transcranial Magnetic Stimulation". This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression. In a double-blind, randomized, sham-controlled fashion, half the participants will receive accelerated theta-burst stimulation while half will ...
What is the current status of trial NCT04739969?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2021-06-15. Estimated completion is 2025-12.
What conditions does trial NCT04739969 study?
This clinical trial studies the following conditions: Treatment-Resistant Depression.
What interventions are being tested in trial NCT04739969?
The interventions under investigation include: Active TBS-DLPFC (DEVICE), Sham TBS-DLPFC (DEVICE).
Who is sponsoring clinical trial NCT04739969?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04739969 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Treatment-Resistant Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04739969's enrollment target sits among peer trials
100 15th of 54 higher than 37 of 54 other Treatment-Resistant Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Treatment-Resistant Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ultrasound Neuromodulation of Circuits and Negative Valence Systems in Treatment-Resistant Depression
RECRUITING · NA
-
Mapping and Modulating the Spatiotemporal Dynamics of Socio-Affective Processing
RECRUITING · NA
-
DBS for TRD With the Medtronic Percept PC
RECRUITING · NA
-
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
RECRUITING · NA
-
PCS in Severe Treatment Resistant Depression
RECRUITING · NA
-
Accelerated Intermittent Theta-Burst Stimulation (aiTBS) in Treatment-Resistant Depression of Bipolar II Disorder
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI